Tag Archives: 2019

Top Pharma News and Developments that Made Headlines in July

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

Amgen signs collaboration agreement with Array BioPharma

2000px-amgen-svg

Amgen and Array BioPharma announced a preclinical license and collaboration agreement in inflammation.

Under the agreement, the two companies will collaborate on the discovery and development of new drugs for autoimmune disorders. Amgen will be responsible for clinical development and commercialization, having exclusive rights to Array’s preclinical program. In turn, upfront and milestone payments will be made by Amgen.

 

Bavarian Nordic partnered with Johnson & Johnson for HIV, HBV shots

j-j-logo

Danish company Bavarian Nordic and Johnson & Johnson have signed a deal worth USD 879M  to develop HIV, HBV shots.

Under the terms of the deal, Bavarian Nordic is granting J&J’s Janssen unit the rights to combine MVA-BN with Janssen’s own AdVac platform in the HIV and HBV programs. In return, Janssen will pay Bavarian Nordic $10 million upfront and up to $836 million in milestones. Bavarian Nordic will design, produce and deliver the MVA needed, while Janssen will handle R&D.

 

Samsung and Merck launched Remicade biosim

merck_logo

Samsung and Merck & Co. launched Renflexis in the US. Renflexis is 35% cheaper than J&J’s anti-inflammatory med.

Last year, Pfizer launched its version, Inflectra, at a 15% discount. Renflexis is the third biosim to launch in the US after Inflectra and Sandoz’s Zarxio, a biosimilar to Amgen’s Neupogen.

 

Gilead’s Vosevi got US FDA Approval

gilead

The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Vosevi tablets, a single-tablet regimen for the re-treatment of chronic hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.

The approval is based on data from the Phase 3 POLARIS-1 and POLARIS-4 studies, which evaluated Vosevi during an interval of 12 weeks.

 

Novo Nordisk and Glooko launch co-marketed app

novo_nordisk-logo

As a result of Novo Nordisk’s partnership with diabetes health tech startup Glooko a new app was launched. It’s dubbed Cornerstones4Care Powered by Glooko, or the C4C app.

The app allows diabetes patients to measure and track blood glucose, activities and meals. It syncs blood glucose and activity data from a wide array of diabetes or exercise devices.

The app is free for registered C4C online users and can be downloaded from the Apple or Google app stores.

 

AstraZeneca partners with Merck to develop and commercialise cancer drugs

astrazeneca-svg

AstraZeneca and Merck & Co have entered a global oncology collaboration to co-develop and co-commercialise the AstraZeneca’s Lynparza and selumetinib for various cancer types.

Under the agreement, the companies will develop and commercialise Lynparza jointly, as monotherapy and in combination with other potential medicines. Furthermore, they will develop and commercialise Lynparza in combination with their own PD-L1 and PD-1 medicines, Imfinzi and Keytruda.

AstraZeneca and Merck will also co-develop and commercialise selumetinib, the former’s selective inhibitor of MEK, that’s being developed for several indications including thyroid cancer.

The 2 companies will share development and commercialisation costs as well as profits from product sales.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

 

5 Successful Tips to Promote Your Conference

This article is brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

If you wanted to promote a conference or an event 15-20 years ago, you would rely heavily on TV, radio, newspapers, magazines and word-of-mouth. Offline media ruled and actually worked…until online media took over.

If you want to promote an event today, you’ll need to be your your audience is and that’s mostly online. Everyone owns a smartphone and is at least on one social media platform. The good part is that you can reach out to a larger number of potential attendees. The bad part is that another 100 conference organizers are trying to get to them first.

We’ve put together this blog post to help you with promoting your conference by analysing 5 ways in which you can reach your target audience. All of them combined should result in higher attendance rates.

 

Start early

Start planning and promoting your conference as soon as you have set the date. You will add details (like avenue, speakers, topics, etc) as time goes by and things begin to settle. The truth is that attendees need time to prepare for a conference. An early promotion gives them more exposure to the event and more time. Also, you can include early bird tickets to boost early registrations that usually work pretty well.

 

Use Social Media

As mentioned in the introduction, you’ll need to be where your potential audience is and social media is one of those places. Through social media platforms, you can communicate with people who would be interested in your conference.

On Facebook, you can create an event and then promote it. This will help the conference gain a lot of traction among those interested to attend. You can also partner with relevant influencers and ask them to share your event or/ and write a few lines about it for their friends and followers.

Create a conference registration page that’s easy to read and to navigate so that when people get on the page they immediately understand the actions they need to take to register – make sure you include a minimum number of registration steps if you don’t want visitors to get tangled and leave the page.

Use hashtags on Twitter and Instagram. On Twitter, hashtags not only help promote your conference but they help attendees network and share with each other even after the conference is over. Good conference hashtags are short and include the conference year.

Don’t shy away from paid social media. This is a very effective way to target people in your industry. Use targeted ads to promote to your industry with links directly to the registration page.

 

Blog about it

Every time you have something new, blog about it and share the news on social media. Also, ask speakers to write a post about their sessions and give a sneak preview of what they’ll be discussing. This way they get more attendees interested in their session, and you get free content to drive ticket sales.

 

Use good old email newsletters

Many see email campaigns as going out of fashion but the truth is they still work pretty well. Some great tools that can help you with this are: Campaign Monitor, MailChimp and Active Campaign. Each lets you send to an uploaded list of recipients, track the open rates and manage subscribing and unsubscribing.

Potential and registered attendees need to learn new fresh information about your event. Emails for early bird closing, new speaker announcements or activities in the event location keep them engaged.

 

Don’t forget about post-conference activities

The truth is that, when you have a recurring event, it’s never over. You have to undertake promo activities prior to the event but also to let fans, speakers, attendees know how great everything went. Post-event interviews, videos, pictures, “thank you for attending” emails work really well.

It’s really important to go out there and show the whole world how amazing everything was so that those who have missed it, come next year and those who came, feel proud that they did.

Last but not least, put yourself in your audience’s shoes. Write what you’d like to know if you were thinking of attending a certain conference, never be a stranger, always be there.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

How 6 Big Pharma Companies Use Twitter to Engage with Audiences

This article is brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

Pharma companies have begun to embrace different communication channels, including social media, to promote their products, present their drug development initiatives and engage with audiences worldwide.

However, make no mistake, social media is not the same for pharma companies as it is for regular users. Without proper planning, controls and staff training, firms risk fines, sanctions and worse, damage to their reputation.

Facebook, Twitter and Pinterest are the main online networks that pharmaceutical companies are eyeing. In this article, we’ll take a look at how pharma companies like Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Pfizer, Merck and Novartis use Twitter to maintain a close connection with their existing and potential patients.

 

Bristol-Myers Squibb

Screen Shot 2017-06-13 at 09.23.23

@bmsnews is the name of New York-based Bristol-Myers Squibb’s Twitter account. The latter was opened in April 2009 and has now has 108.000 followers. The company’s Twitter feed covers everything from drug research results and analysis, clinical collaborations with other pharma companies, to features about the company’s supply chain, and many more.

 

AstraZeneca

Screen Shot 2017-06-13 at 09.24.44

Apart from the main @AstraZeneca Twitter account, the company also has accounts for different countries (UK, US, Canada, etc) and a Twitter profile dubbed @AZhelps. The latter is destined to help people manage and support their health more confidently. The account was opened in 2009 and it currently has over 3000 followers. On the official company account, AstraZeneca posts articles and press releases related to drug discovery, tweets from different conferences, research data, etc. The account now boasts 126.000 followers.

 

GlaxoSmithKline

Screen Shot 2017-06-13 at 09.26.15

@GSK was one of the first pharma companies to be on Twitter. They created their account 10 years ago, in 2007, and now have 146.000 followers. The UK-based company also has a US version @GSKUS that it started in March 2009 and has 73.800 followers. They post R&D updates, info about conferences and events that they’re attending, studies, interviews with patients and employees, etc.

 

Pfizer

Screen Shot 2017-06-13 at 09.27.12

Apart from having separate Twitter accounts for countries like Belgium, France, Turkey, Germany, Austria, etc, @pfizer has an official Twitter profile started in 2009 which now has 206.000 followers and a channel dedicated to media announcements and investor communications dubbed @pfizer_news. Pfizer’s Twitter account is the most followed of all the big pharma Twitter accounts. It mainly focuses on the company’s initiatives in the greater therapeutic arena (like the #QuitSmoking one), cancer research, health tips, polls and surveys, etc.

 

Sanofi

Screen Shot 2017-06-13 at 09.28.33

@sanofi created its official Twitter profile in 2009 and now has 92.600 followers. The French pharma company has more than 18 Twitter accounts. It has handles for different regions – France, Canada, and the US, as well as accounts for different units like its diabetes franchise and its Genzyme unit. On the company’s official Twitter feed you can find posts related to Big Data and health initiatives, collaborations with startups to develop new health solutions, their anti counterfeiting initiatives, vaccines research and development, etc.

 

Novartis

Similar to the other pharma companies, Novartis has several Twitter handles, one for each division of the company (@NovartisPharma for the pharmaceutical division, @NovartisScience, @NovartisCancer) as well as the official page @Novartis. The latter was created in 2008 and has 216.000 followers.

Also, Novartis has one account devoted entirely to oncology clinical trials @NovartisOncCT that allows patients to find out if they qualify for trials.

On their general Twitter account, they update their audience on the latest drug research and development initiatives, post news related to partnerships and collaborations, etc.

Screen Shot 2017-06-13 at 09.29.44

In June 2014, the FDA released its social media guidance regarding the presentation of risk and benefit information which prevents pharma companies from marketing their drugs on social media without presenting the risks associated with their use. However, pharma players have found creative and useful ways of attracting and keeping their audiences engaged. Chapeau!

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

Top Pharma News & Developments that Made Headlines in March

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

FDA approved Roche’s OCREVUS

roche

The US Food and Drug Administration (FDA) approved Roche’s OCREVUS (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis (MS).

OCREVUS reduced relapses per year by half during the two RMS Phase III studies. Furthermore, in a separate PPMS Phase III study, OCREVUS was the first and only treatment to significantly slow disability progression and reduce signs of disease activity in the brain compared with placebo with a median follow-up of three years.

The European Medicines Agency (EMA) has validated OCREVUS’ Marketing Authorisation Application (MAA) which is currently under review.

 

AstraZeneca Partnered with Circassia

astrazeneca-svg

AstraZeneca entered a strategic collaboration with respiratory biopharmaceutical company Circassia Pharmaceuticals plc. The agreement was signed for the development and commercialisation of inhaled respiratory medicines Tudorza and Duaklir in the US.

Tudorza and Duaklir are used for the treatment of chronic obstructive pulmonary disease (COPD). While Tudorza was launched in the US in 2012, Duaklir will be submitted for US regulatory review in 2018.

Under the agreement, AstraZeneca will receive a minority equity stake in Circassia while the latter will lead the promotion of Tudorza and was granted the rights to Duaklir in the US. AstraZeneca will complete ongoing development activities and continue to manufacture and supply both medicines.

 

MedImmune Formed Alliance with Sanofi Pasteur for MEDI8897

Impression

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have formed an alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897.

The two companies will jointly develop and commercialise MEDI8897, a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV).

MedImmune and Sanofi Pasteur will equally share all costs and profits.

 

Mylan in Global Settlement & License Agreements with Genentech and Roche on Herceptin

Mylan_Logo

In March, Mylan has agreed to the terms of a global settlement with Genentech and Roche in what concerns patents for Herceptin (trastuzumab). This enables Mylan to have global licenses for its trastuzumab product.

Under the agreement, Mylan will be able to commercialize its trastuzumab product in markets worldwide. The licenses pertain to all countries except Japan, Brazil and Mexico.

As part of the settlement, Mylan agreed to withdraw its pending Inter Partes Review (IPR) challenges against two US Genentech patents (patent numbers 6,407,213 and 6,331,415).

 

Boehringer Ingelheim Expanded Its Collaboration with Vanderbilt University

boehringer_ingelheim_logo-svg

Boehringer Ingelheim has entered a collaboration with Vanderbilt University. This adds to an already existing collaboration by focusing on the research and development of small molecule compounds targeting the protein SOS. This molecule activates KRAS and triggers a molecular switch that plays a key role when tackling some of the deadliest types of cancer.

This collaboration has led to discoveries that might set the scene for the development of novel cancer treatment options based on molecules that are able to block this critical cancer driver.

 

Merck’s Keytruda Got FDA Nod for Treating Blood Cancer

merck_logo

Merck got a first approval from the U.S. Food and Drug Administration (FDA) under the accelerated approval program for its immunotherapy drug Keytruda as a treatment for a type of blood cancer. Keytruda is already approved for treating lung, head and neck cancers.

FDA’s accelerated approval program allows for quicker approval of drugs that fill an unmet medical need.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are: